Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 11/20 | 0.54 |
| ▸ | SELE | P16581 | 6/20 | 0.54 |
| ▸ | SELP | P16109 | 2/20 | 0.53 |
| ▸ | SELL | P14151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257320 | 0.93 | MAG (0.50) | MAGSELESELPSELL | |
| SCHEMBL11962144 | 0.91 | MAG (0.53) | MAGSELESELPSELL | |
| SCHEMBL11962138 | 0.88 | MAG (0.50) | MAGSELESELPSELL | |
| SCHEMBL12257341 | 0.84 | SELE (0.48) | MAGSELESELPSELL | |
| SCHEMBL13950212 | 0.81 | SELP (0.51) | MAGSELESELPSELL | |
| SCHEMBL12257326 | 0.80 | SELE (0.46) | MAGSELESELPSELL | |
| SCHEMBL11962142 | 0.80 | SELP (0.57) | MAGSELESELPSELL | |
| SCHEMBL12421186 | 0.79 | SELE (0.50) | MAGSELESELPSELL | |
| SCHEMBL11962137 | 0.77 | SELP (0.53) | MAGSELESELPSELL | |
| SCHEMBL13950210 | 0.77 | MAG (0.61) | MAGSELESELPSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | MAG 1778/4885SELE 2/4885SELP 1/4885 |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | MAG 173/4885SELE 158/4885SELP 260/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | MAG 1675/4885SELE 2/4885SELP 1/4885 |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, B3GNT2, FUT5 | MAG 163/4885SELE 622/4885SELP 860/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | MAG 979/4885SELE 3/4885SELP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.